STING1 and cancer: Given its critical role in enhancing anti-tumor immunity, considerable research efforts are focused on developing therapeutic agents that activate the cGAS-STING pathway, such as the direct STING agonists, PARP inhibitors, and paclitaxel, which showed great effect in sensitizing cancer immunotherapy 12-14.